This open-label, multicenter clinical trial examined safety and efficacy of single agent pembrolizumab in the management of the patients with any level of PD-L1 expression (at least 1% of tumor cells or stroma that were PD-L1-positive by immunohistochemistry) receiving pembrolizumab 10 mg/kg every 2 weeks. The gene discussed is CD274; the disease is neoplasm.